Portulaca Oleracea L. Aids Calcipotriol In Reversing Keratinocyte Differentiation And Skin Barrier Dysfunction In Psoriasis Through Inhibition Of The Nuclear Factor Kappa B Signaling Pathway

Psoriasis affects 2-4% of the population worldwide and its treatment is currently far from satisfactory. Calcipotriol and Portulaca oleracea have been reported to exhibit the capacity to inhibit inflammation in psoriatic patients and improve their clinical condition. However, the efficacy of a combination regimen of these two components remains unknown. The aim of the present study was to explore the therapeutic efficacy of P. oleracea extract combined with calcipotriol on plaque psoriasis and its potential mechanism. Eleven patients with plaque psoriasis were treated with humectant containing the active ingredients of P. oleracea extract, with or without 0.005% calcipotriol ointment in a right-left bilateral lesion self-control study. Differences were evaluated by investigation of the clinical efficacy, adverse effects, skin barrier function, histological structure, expression and proliferation of keratinocytes, differentiation markers (cytokeratin 10, filaggrin and loricrin), inflammatory factors [tumor necrosis factor (TNF)-alpha and interleukin (IL)-8], as well as the status of the nuclear factor kappa B (NF-kappa B) pathway. The combination of P. oleracea and calcipotriol was revealed to decrease adverse effects, reduce transepidermal water loss, potently reverse keratinocyte differentiation dysfunction, and inhibit the expression of TNF-alpha and IL-8 and the phosphorylation of the NF-kappa B inhibitor I kappa B alpha. This treatment is therefore anticipated to be suitable for use as a novel adjuvant therapy for psoriatic patients.